跳至主要内容
临床试验/ACTRN12623000519651
ACTRN12623000519651已完成Unknown

The pharmacokinetics and dose response to ingestion of liposomal encapsulated creatine monohydrate in adults

Pharmako Biotechnologies Pty Ltd.0 个研究点目标入组 12 人开始时间: 2023年5月19日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
All

入选标准

  • Adults aged 18-45 with BMI between 18-30. Participants will be required to pass a Health Screen Questionnaire.

排除标准

  • Failure to meet health requirements defined in the Health Questionnaire
  • Known bleeding disorder or blood borne disease
  • Gastrointestinal (e.g., cancer, celiac, irritable bowel) or metabolic (e.g., diabetes, hyperthyroid) disease
  • Taking medications thought to interfere with the study outcomes
  • Currently participating or having participated in another clinical study during the last four weeks prior to the beginning of this study that may affect results
  • Habitual creatine user or planning on starting supplementation during course of the study
  • Recent change in high dietary creatine-containing food (meat, fish) intake or plan to change dietary pattern during participation in the study
  • Oligomenorrhea or amenorrhea in women
  • Currently on hormonal contraceptives including hormonal contracetive pills, hormonal IUD (including Mirena and Jaydess), hormonal injection (such as Depo Provera), or hormonal implant (such as rods)
  • Unable to meet study requirements
  • Women will be asked to book testing sessions between days 3-8 of their cycle.

研究者

发起方
Pharmako Biotechnologies Pty Ltd.

相似试验